Osivax Announces Vaccination of Last Patient in Ph 2a Trial Evaluating OVX836
Osivax Announces Vaccination of First Participant in Trial Evaluating OVX033
Osivax Appoints Dr. Nicola Groth as Chief Medical Officer
LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that it has received a grant of over USD 1.5M from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH). The grant (project number 1R01AI177376) will support preclinical studies evaluating the breadth of protection and immune response induced by the company’s lead, broad-spectrum influenza vaccine candidate, OVX836 against pandemic influenza strains.
Mednow Announces Senior Secured Convertible Debenture Financing by Mednow Management
LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced the publication of promising preclinical proof of cross-protection data against multiple SARS-CoV-2 variants with OVX033, its sarbecovirus vaccine candidate, in a hamster challenge model. The research report article was published under the title, “OVX033, a nucleocapsid-based vaccine candidate provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model,” in Volume 14 - 2023 of the journal Frontiers in Immunology.
LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its new Phase 2a clinical trial (NCT05734040) evaluating broad-spectrum influenza vaccine candidate, OVX836 in combination with Quadrivalent Influenza Vaccines (QIVs).
Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine
Osivax Appoints Dr. Chris Martin, Renowned Biotech Entrepreneur, to its Board of Directors
LYON, France--(BUSINESS WIRE)--Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced the Last Patient Last Visit (LPLV) in two Phase 2a clinical trials evaluating Osivax’ lead T-cell based, broad-spectrum influenza vaccine candidate, OVX836. OVX836 has been developed using the company’s proprietary oligoDOM® nanoparticle technology platform and is designed to produce immune responses against the nucleoprotein (NP), an internal antigen highly conserved across flu strains. The LPLVs were completed in: a dose-optimization study (OVX836-003) underway in Belgium, extended to include elderly participants aged 65 years and older, and a co-administration study being conducted in Australia (OVX836-004) with OVX836 and a quadrivalent inactivated influenza virus (QIV) vaccine. Topline results from both studies are anticipated in the first half of 2023.